| Training set | Validation set | |||
| TB | Control | TB | Control | |
| Subjects n | 60 | 59 | 78 | 98 |
| Age years | 40 (31–52) | 17 (15–18) | 35 (26–45) | 14 (13–15) |
| Males | 40 (67) | 55 (50) | 56 (72) | 49 (50) |
| Place of birth | ||||
| Western Europe | 23 (38) | 59 (100) | 29 (37) | 38 (39) |
| Africa | 19 (32) | 0 (0) | 15 (19) | 1 (1) |
| South America | 2 (3) | 0 (0) | 15 (19) | 50 (51) |
| Eastern Europe | 9 (15) | 0 (0) | 3 (4) | 5 (5) |
| Asia | 6 (10) | 0 (0) | 11 (14) | 4 (4) |
| Unknown | 1 (2) | 0 (0) | 5 (6) | 0 (0) |
| BCG status | ||||
| Yes | 0 (0) | 0 (0) | 10 (13) | 59 (60) |
| No | 0 (0) | 59 (100) | 28 (36) | 38 (39) |
| Unknown | 60 (100) | 0 (0) | 40 (51) | 1 (1) |
| Diagnosis | ||||
| Pulmonary TB | 34 (71) | 0 (0) | 72 (92) | 0 (0) |
| Extrapulmonary TB | 26 (29) | 0 (0) | 6 (8) | 0 (0) |
| Comorbidity | ||||
| None | 53 (87) | 59 (100) | 60 (77) | 98 (100) |
| Diabetes mellitus | 0 (0) | 0 (0) | 5 (6) | 0 (0) |
| HCV | 0 (0) | 0 (0) | 5 (6) | 0 (0) |
| HIV | 7 (13) | 0 (0) | 3 (4) | 0 (0) |
| HIV+HCV | 0 (0) | 0 (0) | 2 (3) | 0 (0) |
| HIV+HBV | 0 (0) | 0 (0) | 1 (1) | 0 (0) |
| Renal transplant + steroids | 0 (0) | 0 (0) | 1 (1) | 0 (0) |
| Tests | ||||
| TST positive/tested | 0/0 (0) | 0/53 (0) | 16/28 (57) | 18/96 (19) |
| TST mm | 0.0 (0–0) | 0.0 (0–0) | 15 (10–18) | 9 (6–12) |
| TST not performed /unavailable | 60 (100) | 6 (10) | 50 (64) | 2 (2) |
| Culture or NAAT +ve/tested | 60/60 (100) | NA | 78/78 (100) | NA |
| Microscopy +ve/-ve/NA | 29 (48)/25 (42)/6 (10) | NA | 59 (76)/18 (23)/1 (1) | NA |
Data are presented as median (interquartile range) or n (%), unless otherwise stated. BCG: bacille Calmette–Guérin; TB: tuberculosis; HCV: hepatitis C virus; HBV: hepatitis B virus; TST: tuberculin skin test; NAAT: nucleic acid amplification test; NA: not available.